High-dose HIV drugs to clear hidden virus
Part of Infections clinical trials.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old.
- You have HIV and are taking a triple antiretroviral drug combo that includes an integrase inhibitor (like dolutegravir or raltegravir).
- Your HIV viral load has been undetectable (below 50 copies) for at least 12 months.
- You have never had HIV treatment failure (where the virus became resistant to your meds).
- You have no serious liver, kidney, or bleeding problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This study tests whether adding a new anti-HIV drug called lenacapavir to your regular HIV treatment can shrink the hidden reservoir of virus in your body. This could be a step toward a cure.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.